Login to Your Account



Sciclone pays $12.8M to clear China FCPA violations

By Shannon Ellis
Staff Writer

Tuesday, February 16, 2016

SHANGHAI – Sciclone Pharmaceuticals Inc. will pay $12.8 million to settle charges that it violated the Foreign Corrupt Practices Act when its international subsidiaries reportedly increased sales by making improper payments to health care professionals employed at state health institutions in China.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription